Gracell Biotechnologies gains as blood cancer therapy shows promise

Gracell Biotechnologies

12/12/2022 11:33

** Shares of Gracell Biotechnologies Inc  GRCL.O  jump 22.3%
to $3.08 premarket
    ** The drug developer says its experimental therapy to treat
multiple myeloma, a type of blood cancer, showed promise in an
early-stage study  urn:newsml:reuters.com:*:nPn5JBPCVa
    ** All patients in the study achieved partial or complete
response to the therapy, and minimal residual disease negativity
in all dose levels
    ** As of Friday's close, stock down ~58% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com))